Ratings by Citi (Samantha Semenkow)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/21/2026 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 5/22/2026 | SAB Biotherapeutics | SABS | New Coverage | Buy (N/A) |
3.81 (3.76) |
-1.31% | Details | |
| 5/8/2026 | Catalyst Pharmaceutical Partners | CPRX | Downgrade | Neutral (Buy) |
31.17 (31.49) |
1.03% | Details | |
| 5/1/2026 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2026 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2026 | Nektar Therapeutics | NKTR | Maintain | Buy (N/A) |
|
Details | ||
| 4/7/2026 | Nektar Therapeutics | NKTR | Maintain | Buy (N/A) |
|
Details | ||
| 4/2/2026 | Biohaven Pharma | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2026 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 3/17/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2026 | Nektar Therapeutics | NKTR | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2026 | BioAge Labs Inc | BIOA | Maintain | Buy (N/A) |
|
Details | ||
| 3/5/2026 | Agios Pharma | AGIO | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2026 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2026 | Larimar Therapeutics | LRMR | Maintain | Buy (N/A) |
|
Details | ||
| 2/10/2026 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 12/17/2025 | Spyre | SYRE | New Coverage | Buy (N/A) |
32.97 (102.74) |
211.62% | Details | |
| 12/17/2025 | Amicus Therapeutics | FOLD | New Coverage | Buy (N/A) |
10.89 (14.49) |
33.06% | Details | |
| 12/9/2025 | WAVE Life Sciences | WVE | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2025 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 11/26/2025 | Nektar Therapeutics | NKTR | New Coverage | Buy (N/A) |
60.35 (75.50) |
25.1% | Details | |
| 11/25/2025 | Agios Pharma | AGIO | New Coverage | Buy (N/A) |
26.49 (32.69) |
23.41% | Details | |
| 11/25/2025 | Rhythm Pharmaceuticals | RYTM | New Coverage | Buy (N/A) |
101.74 (112.85) |
10.92% | Details | |
| 11/17/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 11/12/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2025 | Prime Medicine | PRME | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2025 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2025 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | BioAge Labs Inc | BIOA | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | Roivant Sciences | ROIV | Maintain | Buy (N/A) |
|
Details | ||
| 10/29/2025 | Moonlake Immunotherapeutics | MLTX | Downgrade | Sell (Neutral) |
9.82 (16.59) |
68.94% | Details | |
| 10/22/2025 | BioAge Labs Inc | BIOA | Upgrade | Buy (Neutral) |
5.30 (10.67) |
101.32% | Details | |
| 9/30/2025 | Moonlake Immunotherapeutics | MLTX | Downgrade | Neutral (Buy) |
61.99 (16.59) |
-73.24% | Details | |
| 9/17/2025 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Buy (N/A) |
13.49 (14.49) |
7.41% | Details | |
| 9/2/2025 | Roivant Sciences | ROIV | New Coverage | Buy (N/A) |
11.93 (35.25) |
195.47% | Details | |
| 8/14/2025 | Cabaletta Bio Inc. | CABA | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2025 | Larimar Therapeutics | LRMR | Maintain | Buy (N/A) |
|
Details | ||
| 8/12/2025 | Prime Medicine | PRME | Maintain | Neutral (N/A) |
|
Details | ||
| 8/11/2025 | Immunovant | imvt | Maintain | Buy (N/A) |
|
Details | ||
| 8/1/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 7/16/2025 | WAVE Life Sciences | WVE | New Coverage | Buy (N/A) |
7.71 (5.05) |
-34.5% | Details | |
| 6/30/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2025 | Larimar Therapeutics | LRMR | Maintain | Buy (N/A) |
|
Details | ||
| 6/2/2025 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 5/27/2025 | Prime Medicine | PRME | Downgrade | Neutral (Buy) |
1.23 (3.26) |
165.04% | Details | |
| 5/19/2025 | Prime Medicine | PRME | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2025 | Structure Therapeutics | GPCR | New Coverage | Buy (N/A) |
27.33 (52.13) |
90.74% | Details | |
| 4/17/2025 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2025 | Larimar Therapeutics | LRMR | Maintain | Buy (N/A) |
|
Details | ||
| 3/20/2025 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2025 | Allogene | ALLO | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2025 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 3/12/2025 | Voyager Therapeutics | VYGR | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2025 | 2Seventy Bio Inc. | TSVT | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2025 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 1/7/2025 | Acelyrin Inc | SLRN | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2024 | Larimar Therapeutics | LRMR | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2024 | BioAge Labs Inc | BIOA | Downgrade | Neutral (Buy) |
20.09 (5.30) |
-73.62% | Details | |
| 12/2/2024 | Voyager Therapeutics | VYGR | New Coverage | Buy (N/A) |
6.86 (3.20) |
-53.35% | Details | |
| 10/30/2024 | Larimar Therapeutics | LRMR | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2024 | BioAge Labs Inc | BIOA | New Coverage | Buy (N/A) |
23.86 (10.67) |
-55.28% | Details | |
| 9/30/2024 | Prime Medicine | PRME | Maintain | Buy (N/A) |
|
Details | ||
| 9/9/2024 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Acelyrin Inc | SLRN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/9/2024 | Sana Biotechnology | SANA | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2024 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Buy (N/A) |
|
Details | ||
| 6/24/2024 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 6/17/2024 | Cabaletta Bio Inc. | CABA | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2024 | Sensei Biotherapeutics | SNSE | New Coverage | Buy (N/A) |
0.74 (13.85) |
1771.62% | Details | |
| 5/16/2024 | Prime Medicine | PRME | Upgrade | Buy (Neutral) |
6.76 (1.23) |
-81.8% | Details | |
| 5/8/2024 | Editas Medicine | EDIT | Maintain | Buy (N/A) |
|
Details | ||
| 4/8/2024 | 2Seventy Bio Inc. | TSVT | Maintain | Buy (N/A) |
|
Details | ||
| 3/14/2024 | Catalyst Pharmaceutical Partners | CPRX | New Coverage | Buy (N/A) |
16.62 (31.17) |
87.55% | Details | |
| 2/28/2024 | Editas Medicine | EDIT | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | NGM Biopharmaceuticals | NGM | Downgrade | Neutral (Buy) |
1.53 (1.54) |
0.65% | Details | |
| 2/13/2024 | Larimar Therapeutics | LRMR | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2023 | Acelyrin Inc | SLRN | New Coverage | Neutral (N/A) |
7.16 (2.27) |
-68.3% | Details | |
| 12/8/2023 | Morphic Therapeutic | MORF | New Coverage | Buy (N/A) |
25.78 (56.99) |
121.06% | Details | |
| 12/8/2023 | Prime Medicine | PRME | New Coverage | Neutral (N/A) |
8.39 (6.76) |
-19.43% | Details | |
| 12/8/2023 | Moonlake Immunotherapeutics | MLTX | New Coverage | Buy (N/A) |
51.72 (16.59) |
-67.92% | Details | |
| 12/8/2023 | Allogene | ALLO | New Coverage | Buy (N/A) |
2.56 (2.12) |
-17.19% | Details | |
| 11/29/2023 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 11/17/2023 | Larimar Therapeutics | LRMR | Upgrade | Buy (Neutral) |
2.93 (4.31) |
47.1% | Details | |
| 11/13/2023 | 2Seventy Bio Inc. | TSVT | Maintain | Buy (N/A) |
|
Details | ||
| 10/24/2023 | Editas Medicine | EDIT | Upgrade | Buy (Neutral) |
6.25 (2.95) |
-52.8% | Details | |
| 10/12/2023 | 2Seventy Bio Inc. | TSVT | New Coverage | Buy (N/A) |
4.44 (5.00) |
12.61% | Details | |
| 9/5/2023 | Cabaletta Bio Inc. | CABA | New Coverage | Buy (N/A) |
14.16 (2.79) |
-80.3% | Details | |
| 9/5/2023 | Sana Biotechnology | SANA | New Coverage | Buy (N/A) |
5.35 (3.79) |
-29.16% | Details | |
| 7/18/2023 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2023 | Larimar Therapeutics | LRMR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/18/2023 | 9 Meter Biopharma | NMTR | Maintain | Neutral (N/A) |
|
Details | ||
| 5/10/2023 | Beam Therapeutics Inc | BEAM | Maintain | Buy (N/A) |
|
Details | ||
| 5/3/2023 | NGM Biopharmaceuticals | NGM | New Coverage | Buy (N/A) |
3.83 (1.53) |
-60.05% | Details | |
| 4/25/2023 | Immunovant | IMVT | New Coverage | Buy (N/A) |
15.94 (40.93) |
156.78% | Details | |
| 4/25/2023 | argenx SE | ARGX | New Coverage | Buy (N/A) |
391.12 (864.74) |
121.09% | Details | |
| 3/16/2023 | 9 Meter Biopharma | NMTR | Maintain | Neutral (N/A) |
|
Details | ||
| 2/10/2023 | 9 Meter Biopharma | NMTR | New Coverage | Neutral (N/A) |
2.44 (0.07) |
-97.13% | Details | |
| 12/13/2022 | Beam Therapeutics Inc | BEAM | New Coverage | Buy (N/A) |
44.30 (26.85) |
-39.39% | Details | |
| 12/13/2022 | Larimar Therapeutics | LRMR | New Coverage | Neutral (N/A) |
3.89 (4.31) |
10.8% | Details | |
| 12/13/2022 | Sensei Biotherapeutics | SNSE | New Coverage | Buy (N/A) |
1.72 (0.74) |
-56.98% | Details | |
| 12/13/2022 | Editas Medicine | EDIT | New Coverage | Neutral (N/A) |
9.48 (2.95) |
-68.88% | Details | |
| 7/21/2021 | Ardelyx, Inc | ARDX | Maintain | Buy (N/A) |
|
Details | ||
| 5/21/2021 | Ardelyx, Inc | ARDX | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2020 | Ardelyx, Inc | ARDX | New Coverage | Buy (N/A) |
5.49 (3.94) |
-28.23% | Details |
